Aclarion (NASDAQ:ACON) Upgraded to “Hold” at Wall Street Zen

Aclarion (NASDAQ:ACON) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Aclarion Stock Performance

Shares of ACON stock opened at $3.06 on Friday. Aclarion has a fifty-two week low of $2.34 and a fifty-two week high of $15.08. The firm has a market cap of $2.60 million, a P/E ratio of -0.18 and a beta of 1.44. The business’s 50 day moving average price is $3.08 and its 200-day moving average price is $5.52.

Aclarion (NASDAQ:ACON) last announced its earnings results on Wednesday, March 18th. The company reported ($2.01) EPS for the quarter, beating analysts’ consensus estimates of ($3.60) by $1.59. Aclarion had a negative return on equity of 52.31% and a negative net margin of 9,517.11%.The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. As a group, equities analysts predict that Aclarion will post -263.33 EPS for the current year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.